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Naegleria fowleri, Acanthamoeba spp., Balamuthia mandrillaris, and Sappinia sp. are pathogenic free-living amoebae. N. fowleri
causes Primary Amoebic Meningoencephalitis, a rapidly fatal disease of the central nervous system, while Acanthamoeba spp.
and B. mandrillaris cause chronic granulomatous encephalitis. Acanthamoeba spp. also can cause cutaneous lesions and Amoebic
Keratitis, a sight-threatening infection of the cornea that is associated with contact lens use or corneal trauma. Sappinia pedata
has been identified as the cause of a nonlethal case of amoebic encephalitis. In view of the potential health consequences due
to infection with these amoebae, rapid diagnosis is critical for early treatment. Microscopic examination and culture of biopsy
specimens, cerebral spinal fluid (CSF), and corneal scrapings have been used in the clinical laboratory. For amoebic keratitis,
confocal microscopy has been used to successfully identify amoebae in corneal tissue. More recently, conventional and real-time
PCR assays have been developed that are sensitive and specific for the amoebae. In addition, multiplex PCR assays are available for
the rapid identification of these pathogens in biopsy tissue, CSF, and corneal specimens.
Copyright © 2009 Bruno da Rocha-Azevedo et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
Free-living amoebae (FLA) are found in soil and water habi-
tats throughout the world. These amoebae ingest bacteria,
yeast, and other organisms as a food source. Unlike “true”
parasites, pathogenic FLA can complete their life cycles in
the environment without entering a human or animal host.
Of the many FLA that are found in the environment, four
genera of FLA have been associated with human disease. One
species of Naegleria, N. fowleri, one species of Balamuthia, B.
mandrillaris, and several species of Acanthamoeba can cause
fatal central nervous system (CNS) infections. In addition
to a CNS infection, Acanthamoeba can cause cutaneous
lesions and Amoebic Keratitis, a sight-threatening infection
of the cornea [1–8]. Human infections with these amoebae
have been reported from all over the world [3, 5]. More
recently, a newly recognized pathogen was detected in brain
tissue of a patient with CNS symptoms who survived the
infection. Although the amoebae was not isolated from the
patient, it was identified by light and electron microscopy as
a species of Sappinia. Sappinia sp. has not been shown to be
lethal in humans or experimental animals [9, 10]. Figure 1
shows the morphology of trophozoites of N. fowleri (A),
Acanthamoeba spp. (B), and B. mandrillaris (C), by scanning
electron microscopy.
Pathogenic FLA can be isolated from freshwater lakes,
thermally polluted waters, sediment, thermal springs, swim-
ming pools, soil, air conditioning vents, air, and the domestic
water supply [3, 6, 11–14]. In addition to causing human
disease, FLA also can harbor intracellular pathogenic bacteria
such as Legionella pneumophila and may serve as vectors
of bacterial infections in humans [15, 16]. A number of
clinical FLA isolates from corneal and cutaneous lesions
have been shown to harbor bacterial endosymbionts or
pathogens [16–20]. Laboratory studies, also, have shown that
a number of pathogenic bacteria including Mycobacterium
avium, Burkholderia spp., Escherichia coli O157:H7, and
Vibrio cholerae, can survive and multiply in FLA [6, 21–
26]. Intracellular growth of bacteria within amebae has been
shown to increase bacterial resistance to antibiotics and to
biocides, and to increase bacterial virulence [20, 23–26].
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Since the majority of FLA infections are fatal and
diagnosed postmortem, it is important to recognize the
diseases and to develop more rapid diagnostic methods. The
mode and pathogenesis of infection diﬀer for each of the FLA
that cause human infections.
2. Naegleria fowleri and Primary Amoebic
Meningoencephalitis (PAM)
The amoeboflagellate, N. fowleri, has three morphological
forms in its life cycle, an amoeba or trophozoite stage
(Figure 1(a)) that feeds and divides, a swimming flagellate
that seeks out a new food source, and a resistant cyst that pro-
tects the amoebae from adverse environmental conditions.
N. fowleri causes Primary Amoebic Meningoencephalitis
(PAM), an acute, fulminant, rapidly fatal disease that occurs
generally in previously healthy children and young adults
with a history of swimming and diving and other recreational
activities in fresh water and contaminated swimming pools
[1–3, 27–29]. Two other species of Naegleria, N. australiensis
and N. italica can cause infections in mice but have never
been identified from human infections [5]. Cases of PAM
caused by N. fowleri have occurred also from contaminated
domestic water used for bathing [11, 12]. Infection can occur
when amebae enter the nasal passages, attach to the olfactory
mucosa, and migrate through the cribriform plate alongside
the olfactory nerves. Once in the olfactory bulbs of the brain,
the amebae divide rapidly and death occurs within 7 to 10
days. N. fowleri causes a fulminating hemorrhagic necrosis
of the brain. An inflammatory infiltrate consisting of neu-
trophils, eosinophils, and macrophages is histopathological
characteristic of infected brain tissue. Only trophozoites are
found in the brain [3–5, 29]. Survival from PAM is depen-
dent on rapid diagnosis and treatment of the disease and has
occurred when the disease was recognized early and treat-
ment initiated promptly [30, 31]. Survival rate is improved
when a combination of amphotericin B is used intravenously,
with intrathecal administration of amphotericin B and oral
rifampin and other antifungal agents [30–34]. Amphotericin
B and fluconazole administered intravenously followed by
oral rifampicin resulted in successful treatment of a child
who developed PAM [35]. However, not all patients treated
with Amphotericin B survive [36–38]. Others have suggested
that a triple combination of low dose amphotericin B
administered intravenously (IV) with oral rifampacin and
oral ketoconazole would result in a more favorable outcome
[39]. Azithromycin has been shown to be eﬀective against
N. fowleri in vitro (cell culture) and in vivo (mouse model
of infection) [8]. However, optimal treatment remains to be
developed.
2.1. Symptoms of PAM Infection. PAM is characterized by the
sudden onset of severe frontal headache, fever, nausea, vom-
iting, and rhinitis. These are followed by stiﬀ neck, diplopia,
loss of the sense of smell, confusion, and occasional seizures,
progressing rapidly to coma and death. An elevated white
cell count is usual with a marked increase in neutrophils.
CSF contains neutrophils, and thus a bacterial infection is
often suspected [3–5, 7]. A history that describes contact
with warm water (diving, wakeboarding, water skiing) is
suggestive of PAM [40].
2.2. Laboratory Diagnosis. PAM is a rare disease but almost
always fatal. Therefore, early diagnosis is important in order
to start treatment. The disease is often misdiagnosed because
no distinctive diﬀerences in diagnosis exist to distinguish
PAM from bacterial meningoencephalitis.
2.2.1. Imaging Methods. Computed Tomography (CT) scans
or Magnetic Resonance Imaging (MRI) shows lesions but
these are nonspecific [41–43]. CT scans show obliteration of
the cisterns surrounding the midbrain and the subarachnoid
space [3].
2.2.2. Microscopic Methods. Premortem diagnosis is rare,
but when CSF pressure is low, lumbar puncture can be
performed. CSF is purulent, and when bacteria are not
found, amoebic meningoencephalitis should be considered.
The CSF is cloudy and slightly hemorrhagic with increased
cellularity composedmainly of neutrophils. CSF is character-
ized by low glucose and elevated protein. Direct microscopic
examination of CSF as a wet mount is the method of
choice in the diagnosis of PAM because CSF contains motile
amoebae which can be recognized by light microscopic
observation [5, 44, 45]. N. fowleri can be distinguished
from other FLA that cause CNS infections because amoebae
can transform into swimming flagellates when amoebae
are placed in water. If present in CSF, amoebae can be
identified by staining fixed preparations with Wright’s,
Giemsa, or hematoxylin and eosin (H & E). Although
Gram stain is used in clinical laboratories for detection of
bacteria in CSF, Gram stain is not useful for diagnosis of
amoebae because it does not depict the characteristic nuclear
morphology of the amoebae. Amoebae can be mistaken as
macrophages, butN. fowleri nucleus contains a large, central,
round nucleolus which should distinguish it from host cells
[3, 27, 44, 45].
Polyclonal antibodies produced in rabbits or monoclonal
antibodies can be used to identify amoebae in tissue sections
and CSF. Amoebae in CSF can be identified by specific indi-
rect immunofluorescent antibody assays using a polyclonal
or monoclonal antibody to the amoeba in conjunction with
a flouresceinated secondary antibody [3, 45, 46].
Biopsy material should be fixed in 10% neutral buﬀered
formalin for histological examination. Amoebae can be
observed in biopsied brain tissue following H & E staining
or by immunoperoxidase staining using antibodies to the
amoebae. Only trophozoites are found in brain tissue; cysts
are not observed [3].
A commercially available enzyme-linked immunosor-
bent assay (Indicia, Oulin, France) based on the use of a
monoclonal antibody (5D12) that recognizes a glycosylated
epitope onN. fowleri can be used to diagnose infections. This
monoclonal antibody can be used to distinguish N. fowleri
from other species of Naegleria, and from other FLA in tissue
and in environmental samples [46, 47].
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Figure 1: Fine morphology of trophozoites of N. fowleri, (a) Acanthamoeba spp., (b) and B. mandrillaris, (c) by Scanning Electron
Microscopy. Bars represent 5µm.
2.2.3. Culture Methods. CSF or biopsied brain tissue should
be kept and transported at room temperature to the
diagnostic laboratory. This material can be inoculated onto
tissue culture cells (Vero, fibroblasts) and incubated at 37◦C
in the presence of the antibiotics, penicillin-streptomycin.
Fungicides are lethal to the amoebae. Amoebae that are
present will multiply and destroy the monolayer in 24 to 48
hours. Biopsy tissue also can be placed on 1.5% nonnutrient
agar coated with a layer of bacteria (Escherichia coli). The
amoebae will emerge from the tissue, ingest the bacteria, and
divide. The amoebae, then, can be observed on the agar using
an inverted light microscope [3, 44, 45, 48].
2.2.4. Serology. Antibodies to Naegleria spp. have been
identified in healthy individuals [49, 50]. Since PAM is a
rapid disease, serological tests for an increase in antibody
titer are not always helpful. Generally, there is not a rise in
antibody titer although a rise in antibody has been observed
in a patient that was successfully treated and survived the
infection [30].
2.2.5. Polymerase Chain Reaction (PCR) Assays. More rapid
molecular techniques are now available in research labora-
tories, but these methods generally are not available in most
clinical laboratories. Highly specific and sensitive PCR and
real-time PCR assays have been developed for the detection
of N. fowleri in clinical and environmental samples [51–
57]. A PCR assay using primers for the complete ribosomal
internal transcribed spacer region (ITS) has been developed
that allows for the discrimination of Naegleria species, and
a species specific assay allows for detection of N. fowleri
[51, 52]. A PCR assay that detects N. fowleri in fresh brain
tissue as well as in formalin-fixed paraﬃn-embedded brain
tissue also has been reported [56]. Recently, Qvarnstrom et
al., [57] developed a fast and sensitive multiplex real-time
PCR assay based on the use of probes targeting the partial or
full length nuclear small subunit ribosomal genes (18S rRNA
gene) for simultaneous detection of Naegleria, Balamuthia,
and Acanthamoeba [57]. This PCR assay is species specific
for N. fowleri and B. mandrillaris and genus specific for
Acanthamoeba. Thus, this assay can identify which amoebae
is present in a CSF sample or a brain biopsy specimen from
an amoebic encephalitis patient. The detection limit for this
assay was shown to be one amoebae per sample.
3. Acanthamoeba spp.
Acanthamoeba is one of the most commonly isolated amoe-
bae in environmental samples. Acanthamoeba is ubiquitous
and found in a variety of habitats including domestic water
supplies, hospital water, dental water units, air, soil, and
water. Acanthamoeba has two morphological forms in its
life cycle, a trophozoite (Figure 1(b)) and a cyst stage. Both
stages can be found in tissues of infected humans and in
the environment. The trophozoite is the dividing form and
is thought to be the infective stage. The cysts are dormant
and protect the amoebae from harmful environments. The
cysts are resistant to biocides, chlorination, and antibiotics.
Several species of Acanthamoeba can cause Granulomatous
Amoebic Encephalitis (GAE), cutaneous acanthamoebia-
sis, or Amoebic Keratitis (AK). AK is a sight-threatening
infection of the cornea that occurs in immune competent
individuals, mainly contact lens users. GAE, also known
as Acanthamoeba Granulomatous Encephalitis (AGE), is a
rare, chronic, progressive infection of the CNS that may
involve the lungs [58]. GAE is usually associated with
an underlying debilitating disease or immune suppressed
individuals including HIV-AIDS patients, diabetics, individ-
uals undergoing organ transplants or cancer chemotherapy,
and drug abusers [6, 7, 58, 59]. Cutaneous lesions caused
by Acanthamoeba also have been described. Cutaneous
acanthamoebiasis has been reported more frequently in HIV
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positive patients than in other conditions [60–66]. The
manifestations of cutaneous infection include the presence
of numerous hard erythematous nodules, papules, or ulcers
along the patient’s body [62–67]. The presence of both skin
lesions and CNS symptoms occurring simultaneously can be
suggestive of an Acanthamoeba infection [58].
3.1. Symptoms of GAE. GAE symptoms include headaches,
slight fever, seizures, hemiparesis, cranial nerve palsies,
personality changes, nausea, stiﬀ neck, depressed level of
consciousness and coma, typical clinical signs of a localized
encephalopathy [5–8]. The clinical signs of GAE are not
specific. Thus, the disease is often misdiagnosed as bacterial
leptomeningitis, tuberculous meningitis, viral encephalitis,
toxoplasmosis, fungal infections, neurocysticercosis, or a
brain tumor [5, 6, 68–71].
3.2. Diagnostic Methods
3.2.1. Imaging Methods. Brain imaging methods, such as CT
and MRI, have been used to visualize brain lesions caused
by Acanthamoeba, but the lesions themselves are not specific
for GAE [41–43]. Multifocal low-density lesions in both
cortical and subcortical regions of the brain can be observed
using CT scans. Enhanced CT normally shows the presence
of progressive hydrocephalus, with meningeal thickening,
pseudotumoral lesions, large isolated lesions, or multiple
oval lesions. Multifocal lesions, edema, and multiple ring-
enhancing lesions are commonly observed in GAE patients
byMRI. Despite these characteristics, both CT andMRI have
limited diagnostic value for GAE [5, 7, 41–43, 68–73].
3.2.2. Microscopic Methods. The definitive diagnosis of GAE
is the detection of the amoeba in tissue or isolation of the
amoeba. To achieve visual detection of both Acanthamoeba
trophozoites and cysts in brain tissue, skin lesions, or cere-
brospinal fluid (CSF), both light and electron microscopy
can be used. Acanthamoeba trophozoites can be distin-
guished from host inflammatory cells such as macrophages
mainly by their nuclear structure, since Acanthamoeba
possesses a rounded nucleus and a large central nucleolus,
forming a halo [3, 6, 59]. However, it is not possible to
diﬀerentiate Acanthamoeba trophozoites from pathogenic B.
mandrillaris trophozoites by light microscopy, since both
amoebae possess the same nuclear structure [7]. Biopsy
or autopsy specimens should be formalin-fixed, paraﬃn-
embedded, and stained withH&E [74]. Other types of histo-
logical staining have been used, including Periodic Acid Shiﬀ,
Gomori’s methenamine silver, or trichome. These stains
appear to be eﬀective in identifying cysts [75, 76]. Acridine
orange and calcofluor white have been used successfully to
observe Acanthamoeba cysts in tissues [6, 77, 78].
Brain granulomas, necrosis with the presence of multi-
nucleated cells, inflammatory infiltrates, and amebas (both
trophozoites and cysts) surrounding blood vessels [3–5]
can be observed in biopsied tissue stained with H & E.
Amoebae, also, can be detected in CSF in wet preparations or
Giemsa stained slides of CSF sediments [29, 79, 80]. For the
diagnosis of cutaneous acanthamoebiasis, light microscopic
examination of H & E stained skin biopsies demonstrates
the presence of granulomas, areas of necrosis, inflammatory
infiltrates, and vasculitis containing both trophozoites and
cysts of Acanthamoeba [62, 64, 67, 75, 81].
The use of both fluorescence microscopy and immuno-
histochemistry in brain and skin tissue sections is eﬃcient
methods to specifically detect Acanthamoeba [82–87]. Anti-
Acanthamoeba antibodies generated in rabbits can be used to
identify amoebae in tissue. Patient specimens are incubated
with anti-Acanthamoeba antibodies followed by a secondary
antirabbit IgG associated with a fluorescent marker to detect
both trophozoites and cysts [74]. More recently, species-
specific monoclonal antibodies were developed to use as
an important diagnostic and epidemiological tool. These
monoclonal antibodies recognize A. castellanii, A. polyphaga,
A. lenticulata, and A. culbertsoni, react with formalin-fixed,
paraﬃn-embedded infected tissues, and recognize both the
trophozoite and cyst stages of the amoebae [88].
Transmission electron microscopy (TEM) also can be
used as a tool to diﬀerentiate cysts and trophozoites of
Acanthamoeba from host cells and from other amoebae, such
as B. mandrillaris [63, 70, 89, 90]. However, this technique
is expensive; sample preparation is time consuming and
requires personnel with expertise.
3.2.3. Culture Methods. Isolation and culture of Acan-
thamoeba can be performed by placing brain or skin
biopsy/autopsy samples on 1.5% nonnutrient agar plates
covered with a layer of Escherichia coli or Enterobacter
aerogenes [3, 7, 48, 58, 83, 91]. Depending on the density
of amoebae, Acanthamoeba can be observed after 24 hours
of inoculation. Samples, also, can be placed on tissue culture
cells in the presence of antibiotics (penicillin-streptomycin
and gentamicin) in which case the amoebae destroy the cell
monolayer in 24 to 48 hours depending on the number of
amoebae present [3, 6, 59].
3.2.4. Serology. To detect Acanthamoeba infections, an
increase in antibody titer can be an indication of infection.
For this evaluation, indirect immunofluorescence (IIF) is
performed using serial dilutions of serum from an individual
suspected of having Acanthamoebiasis, followed by incu-
bation of the sera with slides containing fixed amoebae or
amoebic extracts. The detection can be achieved by adding
an anti-IgG antibody associated with a fluorescent label
such as FITC, and antibody detection and titration can be
determined by fluorescence microscopy [92]. Acanthamoeba
infected individuals possess high antibody titers (between
1 : 256 and 1 : 1024) in serum while healthy individuals
who have been exposed to Acanthamoeba in the environment
have low antibody titers, usually not higher than 1 : 80
[82, 92–96]. Thus, IIF can be a useful tool to confirm
infection in patients who are suspected of being infected
withAcanthamoeba [96].Western immunoblot analysis, also,
has been used to demonstrate antibodies to Acanthamoeba
in human serum [97]. An ELISA method utilizing whole
fixed trophozoites rather than disrupted amoebic extracts
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as the antigen source was developed and shown to be an
eﬀective tool for identifying antibodies to Acanthamoeba in
the clinical laboratory setting [98].
3.2.5. PCR. Detection of Acanthamoeba can be rapidly
achieved by using molecular methods. For diagnostic
purposes, the detection of Acanthamoeba at the genus
level is suﬃcient to recognize whether an individual is
infected. Molecular identification of Acanthamoeba can
be performed by polymerase chain reaction assays [99–
101]. The complete DNA gene sequence of the 18S
ribosomal RNA gene (18S rDNA) permitted the design
of a reliable primer pair specific for Acanthamoeba
genus, called JDP1 and JDP2. Use of the JDP1 (forward
primer) 5′-GGCCCAGATCGTTTACCGTGAA and the JDP2
(reverse primer) 5′–TCTCACAAGCTGCTAGGGAGTCA,
respectively, results in a specific amplimer of 500 bp, called
ASA.S1. An advantage of this PCR assay is that it detects
all known Acanthamoeba subgroups [100]. This PCR assay
has been successfully used to detect Acanthamoeba in the
environment as well as in patients with GAE and cutaneous
acanthamoebiasis [83, 102–105]. However, DNA amplifica-
tion from cysts is a troublesome task. Thus, treatment of
cysts with proteinase K prior to DNA extraction has been
suggested to increase the positive results by PCR assays
[106].
Studies have shown that the majority of GAE and AK-
causing amoebae have a specific PCR product (these amoe-
bae are included in a subgroup called T4), when primers
to amplify the small subunit rRNA genes (SSU rDNA) are
used [107]. Mitochondrial DNA PCR, also, has been used
successfully to detect Acanthamoeba from brain slices and
CSF [108, 109]. Real-time PCR has been used as a fast tool
to diﬀerentially identify free-living amoebae and to diﬀer-
entiate Acanthamoeba from N. fowleri and B.mandrillaris
[57, 110]. A real time PCR assay developed by Rivie`re et
al.,[110] utilizes Taqman technology to detect 18S ribosomal
DNA (rDNA). This assay, based on the Acanthamoeba T4
genotype, does not detect other genotypes such as T10. The
real time PCR assay developed by Qvarnstrom et al., [57]
is a triplex assay to distinguish Acanthamoeba from other
pathogenic FLA and is more complete in that it was designed
to detect a broader range of Acanthamoeba genotypes. Both
real time assays have been validated by testing a number of
positive and negative clinical samples [111].
4. Acanthamoeba spp. and
Amoebic Keratitis (AK)
In contrast to GAE, which is a chronic infection, AK is an
acute, painful infection that can occur in immune competent
individuals. This disease is related to the use of contact
lenses or previous corneal trauma. When AK is not treated
promptly, loss of visual acuity and blindness can occur
[6, 7, 58, 59, 112–116].
4.1. Symptoms of AK. Initial symptoms of AK are not
specific and include disproportional eye pain, photophobia,
eye redness, and tearing, usually aﬀecting one eye [116].
However, bilateral AK has been described, as a compli-
cation of the initial infection [116]. Using a slit-lamp,
corneal inflammation leading to formation of a ring-like
stromal infiltrate can be observed. Furthermore, corneal
epithelial erosion, irregularities, and edema are present.
The radial perineural distribution of the infiltrate (radial
keratoneuritis) is characteristic for AK, similar to the type
of infiltration observed in Pseudomonas aeruginosa keratitis
[112–115, 117–120]. Later stages of infection can result
in epithelial denudation and stromal necrosis. Contact
lens usage and/or incidents of corneal trauma are strong
indicators for AK [121–123]. Despite the clinical picture, AK
is often misdiagnosed as herpes or bacterial keratitides which
exhibit similar clinical symptomatology [114, 124, 125].
4.2. Diagnostic Methods
Diagnosis of AK can be undertaken by analysis of the clinical
appearance of the cornea and by the demonstration of
amoebae in the cornea [112, 125].
4.2.1. Microscopic Methods. The detection of Acanthamoeba
can be achieved by analysis of a corneal biopsy. However,
corneal scraping has been an eﬃcient and noninvasive
method used to isolate amoebae and to diagnose Acan-
thamoeba keratitis [126]. After scraping, samples can be
smeared on glass slides. Light microscopy is an eﬃcient
means to detect Acanthamoeba in corneal scrapings, in
biopsy samples, and in keratoplasty specimens. Acan-
thamoeba can be detected in wet-mount preparations of
corneal scraping, using 10% KOH [126–132]. Moreover,
impression cytology was able to remove amoebic specimens
of an AK patient [132]. H & E and Giemsa stains have
been used successfully to detect both trophozoites and
cysts of Acanthamoeba. Cysts stained by Giemsa or H
& E are clear, bright with polyhedric or stellate shaped
cysts, while trophozoites, with the central nucleolus and
vacuoles, are more diﬃcult to detect, since they can resemble
inflammatory cells [112, 115, 129, 130, 133–135]. PAS stain
also has been used for detection of cysts [128, 136]. As
described previously, IIF assays and immunofluorescence
microscopy can be used to detect Acanthamoeba in brain
and skin tissue, as well as in corneal specimens, contact
lenses, and lens cases [134, 137, 138]. Immunoperoxidase
technique is also eﬃcient to detect Acanthamoeba in host
tissue [121, 134]. Cysts and trophozoites are easily detected
by transmission electron microscopy [133].
Fluorescent stains have been used to detect Acan-
thamoeba cysts in corneal samples. Calcofluor white is a
fluorescent compound that is able to bind cellulose in the
cell wall of Acanthamoeba cysts found in corneal scrapings
and paraﬃn-embedded sections of corneal tissue [138, 139].
Furthermore, specimens previously stained with H & E,
and other stains can be stained subsequently with calcofluor
white, which is rapid and eﬃcient but requires a fluorescence
microscope. It is also important to note that in mixed fungi,
Acanthamoeba infections, both pathogens will be stained,
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since both amoebic cysts and fungi cell walls are possi-
ble targets for calcofluor white. Acridine orange, another
fluorochromatic dye, has been used for rapid diagnosis of
AK [78]. The use of fluorescent dyes may lead to false-
positive staining patterns of cell debris [129, 130]; therefore,
an experienced observer and a fluorescence microscope are
necessary for a proper diagnosis.
The use of in vivo confocal microscopy to detect
Acanthamoeba in corneal tissue at distinct depths, in real
time, without any invasive procedure has been successfully
used to diagnose AK [140–148]. In a recent Chicago-
area outbreak, in conjunction with other methods, such
as culturing or light microscopy, confocal microscopy was
used to detect Acanthamoeba [148]. High-contrast rounded
bodies, indicative of amoebic cysts, are commonly observed
[143, 146, 147]. Limitations of confocal microscopy as a
definitive diagnostic tool for AK have been presented [149].
However, studies have shown that when confocal microscopy
was used by experienced operators, the technique is sensitive
and specific for detection of Acanthamoeba in corneal tissue
[148].
4.2.2. Culture Methods. As described previously for GAE,
culture of amoebae from corneal biopsies or scrapings
and washes from contact lenses or lens cases is still the
most common, cheap, and eﬃcient method to detect Acan-
thamoeba. Samples from the infected cornea are inoculated
on 1.5% nonnutrient agar plates covered with E. coli or other
nonmucoid bacteria. The plates can be incubated at 28–
30 ◦C for days to weeks, which depends on the number of
amoebae in the samples. The presence of amoebae can be
checked by using an inverted microscope [48, 150].
4.3. PCR. As described previously for GAE and cutaneous
lesions, PCR probes have been used, also, to confirm the pres-
ence of amoebae in corneal biopsies and scrapings, contact
lenses, lens cases, lens solutions, and also in the environment
[57, 100, 110, 151, 152]. Moreover, PCR is an eﬃcient
method to detect Acanthamoeba in tear samples [153], a
completely noninvasive way to perform AK diagnostics. The
sensitivity of PCR methods to diagnose AK was compared
with direct microscopic examination and culture, and it was
reported that PCR was more sensitive than morphological
detection [154]. Two real time PCR assays have been
validated to use as diagnostic tests for AK [57, 110]. However,
it has been shown that a number of commonly used topical
ophthalmic drugs have an inhibitory eﬀect on PCR assays
[155]. Thus, it is important that ophthalmologists rinse the
eye surface extensively to remove any inhibitory substances to
minimize the risk of misdiagnosis due to false negative PCR
results.
5. Balamuthia mandrillaris and
Balamuthia Amoebic Encephalitis (BAE)
B. mandrillaris is the only species of Balamuthia known
to cause infection in humans or animals. Balamuthia was
first isolated from the brain of a mandrill baboon that
died at the San Diego Zoo from meningoencephalitis. The
amoebae was first described as a leptomyxid amoebae but
later identified and named Balamuthia mandrillairs [156–
159]. The life cycle of Balamuthia consists of a trophozoite
(Figure 1(c)) and a cyst state. The amoeba is found in
soil, but its presence in water has been suggested based on
cases of BAE occurring in animals and humans that had a
history of swimming in stagnant water [160–163]. Although
Balamuthia is considered an opportunistic pathogen, it can
cause disease in both immune compromised and immune
competent individuals. Infections can occur in children
and adults. The incubation period of BAE is extended,
and therefore the source and mode of infection have not
been definitively determined. It has been suggested that
the portal of entry may be via cutaneous lesions, nasal
passages, or inhalation via the respiratory tract with subse-
quent hematogenous spread to the brain and other organs
[159].
5.1. Symptoms of BAE. The encephalitis caused by B. man-
drillaris, also, is a rare disease with nonspecific symptoms.
Symptoms of BAE are chronic and include headaches,
nausea, vomiting, fever, myalgia, seizures, weight loss,
hemiparesis, and speech diﬃculties, usually associated with
previous skin granulomatous lesions. The aforementioned
symptoms are confusing, since they are similar to other brain
infections, including tuberculosis, toxoplasmosis, cysticerco-
sis, meningitis, and also brain tumors [7, 158, 164–169].
5.2. Diagnostic Methods
5.2.1. Imaging Methods. Brain lesions caused by B. man-
drillaris can be detected by neuroimaging, such as CT scans
and MRI [170–172]. Focal enhancing lesions, cystic lesions,
edema, and hydrocephalus can be observed [172, 173]. The
lesions can mimic other types of disease, such as gliomas,
brain abscesses, and hematomas [7]. Thus, the lack of
specificity makes the proper diagnosis by imaging methods
diﬃcult.
5.2.2. Microscopic Methods. Light microscopy can be used
to detect the presence of B. mandrillaris in host tissue.
Balamuthia has often been identified as Acanthamoeba in
tissue because both amoebae cause granulomatous amoebic
encephalitis. Amoebae can be observed from brain and
skin biopsies and autopsies [174–176]. Unlike infection with
N. fowleri, B. mandrillaris is generally not seen in CSF
preparations, although it has been isolated from CSF of a 33-
year-old patient that died of BAE [7, 177]. In the majority of
cases described, B. mandrillaris was observed in brain biopsy
specimens embedded in paraﬃn and processed for H&E
[158, 170, 175, 178]. Areas of inflammation, granulomas,
and the presence of trophozoites and cysts of B. mandrillaris,
especially around blood vessels, are observed [165, 169, 179].
Trophozoites show an oval-to-round shape, with a single
nucleus and a large nucleolus, while cysts are rounded with
a thick wall. However, these morphological characteristics
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are not adequate to diﬀerentiate B. mandrillaris from Acan-
thamoeba spp., and also the ability to diﬀerentiate these
amoebae from host macrophages requires expertise [7, 84].
Antibodies are crucial to the specific detection of B.
mandrillaris in tissues. Studies have confirmed, both in
biopsies and autopsies, the presence of B. mandrillaris in
brain and skin tissue [84, 157, 170, 174, 178]. Usually,
paraﬃn-embedded specimens are sectioned and incubated
with rabbit anti-Balamuthia serum, and a FITC-conjugated
secondary antibody against rabbit IgG is used to detect
amoebae with high degree of specificity [159].
It is possible to identify B. mandrillaris in biopsies
with the use of transmission electron microscopy (TEM).
Unlike host cells, trophozoites contain a characteristic
dense nucleolus, and the cytoplasm contains many vesicles.
Furthermore, TEM can distinguish B. mandrillaris from
Acanthamoeba, since B. mandrillaris possesses a tripled-
walled cyst, a distinctive trait when compared to the doubled-
walled cyst of Acanthamoeba [158, 159].
5.2.3. Culture Methods. Isolation of B. mandrillaris from
biopsy specimens is possible; however amoebic growth is
slow and also requires the use of tissue culture cells as a
food source, since B. mandrillaris does not feed on bacteria
[48, 157–159]. This is not a recommended method.
5.2.4. Serology. One of the characteristics of B. mandrillaris
infection is the high concentration of antibodies to the
amoebae in host serum [180–182]. It is possible to determine
an infection in humans suspected of having BAE by the
presence of antibodies against B. mandrillaris in their sera
using enzyme-linked immunoassays (ELISAs). This method-
ology was used to screen a group of encephalitis patients
in California, and it was shown that 7 individual samples
from 290 were positive for B. mandrillaris [181]. Antibodies
to B. mandrillaris do not cross-react with other amoebae
[180]. Thus, ELISA technique can be useful for screening
of samples containing large number of individuals. More
recently, flow cytometry was successfully used to detect and
quantify antibodies against B. mandrillaris in both healthy
and diseased individuals [182].
5.2.5. PCR. Rapid and highly specific B. mandrillaris detec-
tion can be achieved by using polymerase chain reaction
methodology. B. mandrillaris is a well-defined phylogenetic
species, with no SSU rDNA sequence variation between
isolates and low levels of mitochondrial DNA variation.
Booton and coworkers [183, 184] developed specific primers
from a portion of the mitochondrial rRNA gene (rns). The
PCR reaction of these primers resulted in a 1075 bp product,
where the product is specific for B. mandrillaris and not for
Acanthamoeba. Detection of B. mandrillaris was performed
successfully on clinical samples using these primers, both
in brain tissue, and CSF [177, 185, 186]. The sensitivity of
the PCR detection was tested, and it was observed that 0.2
amoebae were enough for amplification, since mitochondrial
DNA had been used [186], indicating that the employment
of PCR was an eﬃcient diagnostic tool. The eﬃcacy of
PCR method was compared with IIF as a diagnostic tool
on archival brain tissue and a high degree of agreement
was reported [109]. By using distinct primers, a multiplex
real time PCR to detect B. mandrillaris was developed, with
rapid test completion time and high sensitivity, detecting
one amoebae per sample [57]. This multiplex assay has
been validated and is recommended for detection of FLA in
clinical samples [111]. More recently, a real time PCR assay
was developed for B. mandrillaris, targeting the RNAase P
gene [187]. Sensitivity and specificity were observed, with the
probes able to detect small amounts of amoebic DNA.
6. Sappinia pedata and Sappinia
Amoebic Encephalitis (SAE)
The free-living amoeba, Sappinia, a newly discovered human
pathogen of the central nervous system (CNS), can cause
amoebic encephalitis in humans [9, 10]. There are two
species of Sappinia, S. pedata and S. diploidea. Sappinia has
a worldwide distribution and has been isolated from elk and
buﬀalo feces, soil contaminated with bovine feces, decaying
ground plant litter and fresh water [188, 189]. The life cycle
of Sappinia consists of two stages, a trophozoite and a cyst
[190]. The first and only case of amoebic encephalitis caused
by Sappinia sp. occurred in a previously healthy immune
competent adult male who survived the infection. The
incubation period and the route of infection are unknown
but thought to be by inhalation through the nasopharynx
or by hematogenous spread to the brain [9]. The amoeba
that caused this encephalitis was originally identified as S.
diploidea but has now been identified as S. pedata using
molecular techniques to identify the amoeba (191,192). It is
not known whether the other species (S. diploidea) can cause
infections in human or animal hosts.
6.1. Symptoms of SAE. In the single case of Sappinia amoe-
bic encephalitis that has been reported, a sinus infection
occurred prior to the onset of symptoms. The individual
developed nausea, vomiting, bifrontal headache, photopho-
bia, and blurry vision. A loss of consciousness occurred
for a brief period [7, 9, 10, 191]. A successful outcome in
this patient was reported after surgical excision of a tumor-
like mass in the brain and treatment using azithromycin,
intravenous pentamidine, itraconazole, and flucytosine [10].
6.2. Diagnosis. A solitary tumor-like mass without an abscess
wall in the brain can be observed by MRI for Sappinia
encephalitis. The excised mass or biopsy tissue can be fixed
and embedded in paraﬃn. Brain sections stained with H &
E may exhibit necrotizing hemorrhagic inflammation con-
taining amoebae. Eosinophils and granuloma formation are
lacking. Sappinia amoebae can be distinguished from other
FLA by the presence of a distinctive double nucleus in which
the 2 nuclei are closely apposed with a central flattening
[188, 189]. Two nucleoli are found in the double nucleus.
These structures can be observed in paraﬃn sections stained
with H & E, Giemsa, or Periodic Acid Schiﬀ. The amoebae
are readily observed in cryostat sections stained with H & E
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[7, 10, 191]. Brain tissue can be fixed in glutaraldehyde and
prepared for transmission electron microscopy to visualize
the amoebae in tissue.
6.3. PCR. Sappinia pedata and S. diploidea can be identified
and distinguished by amplification of the SSU rDNA using
universal eukaryotic SSU primers followed by an Internal
Transcribed Spacer PCR assay. Primers used in the ITS
PCR assay are ITS1–P1F5′-GTA ACA AGG TATCCG TAG
GTG AAC C-3′ and ITS2–P4R: 5′TCC TCC GCT TAT TGA
TAT GC—3′ [190]. The amoebae originally identified as S.
diploidea in the single reported case of Sappinia amoebic
encephalitis was later identified as S. pedata using newly
developed real-time PCR assays based on 18S rRNA gene
sequences [191]. The assay specific for Sappinia can be
incorporated into the multiplex PCR assay described by
Qvarnstrom et al., [57] that distinguish Acanthamoeba, B.
mandrillaris, andN. fowleri for simultaneous detection of the
four genera of FLA that cause infections in humans [191].
6.4. Culture. Sappinia can be cultured on nonnutrient agar
coated with bacteria and on tissue culture cells [7].
7. Conclusion: The Importance of
Early Diagnosis
Although infections with FLA are considered rare, there
has been an increase in the number of reported cases in
recent years. CNS infections caused by pathogenic free-
living amoebae (FLA) are for the most part fatal. Corneal
infection caused by Acanthamoeba can lead to blindness
or vision impairment in AK. Recently, it has been shown
that there is a greater chance of cure if these infections
are detected early and treated timely. However, a fast and
eﬃcient diagnosis depends on two variables: the familiarity
of practitioner with the symptomatology and treatment of
FLA infections, and also the appropriate material to process
for a fast and definitive diagnosis. At the present time, it is
not known whether FLA infections are rare because they are
underreported or due to misdiagnosis. Most infections have
been diagnosed postmortem. It is not possible to determine
the rarity of these infections, since these infections are
relatively unknown, and in many cases autopsies are not
performed.
The number of contact lenses users around the world has
increased, and consequently AK outbreaks have been more
frequent, which requires a faster public health response.
GAE and cutaneous acanthamoebiasis can be one of the
most frequent secondary diseases in AIDS-HIV patients and
in other immunosupressed individuals, since Acanthamoeba
is found throughout the world. The dramatic increase in
BAE could reflect the potential of this infection to be a
commonworldwide disease. The increased incidence of PAM
caused by N. fowleri in recent years may be due to greater
recreational activity in warm water lakes and parks. PAM
could be avoided with greater awareness of the disease, using
public education programs, closing of swimming pools that
are improperly chlorinated, and wearing nose clips while
diving and engaging in water activities when the nose is
submerged. The recent finding of S. pedata as a pathogen of
the CNS in humans suggests that other free-living amoebae,
not yet identified, may be causative of amoebic of amoebic
encephalitis.
A more rapid clinical response could provide higher
survival rates since treatment is available. Thus, fast and
eﬃcient diagnostic tests are pivotal for treatment success.
The availability of PCR probes is a promising procedure
to obtain fast and specific, confirmatory diagnosis of PAM,
GAE, AK, BAE, and SAE in a timely fashion for eﬃcient
treatment. To this end, a multiplex PCR assay is available
and has been validated as an important and specific tool to
identify, N. fowleri, Acanthamoeba spp., and B. mandrillaris
in clinical specimens [57, 111] but only a few reference
laboratories are capable of doing diagnostic detection of
FLA [191]. Additionally, a PCR assay has been developed
to detect Sappinia in clinical samples [191]. In conclusion,
the recognition of these diseases and specific diagnostic tests
could lead to earlier treatment and diminish the severity and
lethality of these infections in the human host.
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